Scientific Committee

  • Sean Hennessy, PharmD, PhD

    Dr. Hennessy’s primary field of interest is pharmacoepidemiology, which is the study of the use and effects of medications in populations. Dr. Hennessy’s research has been funded by the Agency for Healthcare Research and Quality (AHRQ), the National Institutes of Health (NIH), pharmaceutical companies, and private foundations. He is currently leading NIH-funded studies on drug-induced sudden death and ventricular arrhythmia, and on the clinical importance of drug-drug interactions. He is the principal investigator of Penn’s AHRQ-funded “Developing Evidence to Inform Decisions About Effectiveness” (DEcIDE) center, and a co-principal investigator of Penn’s AHRQ-funded Center for Education and Research on Therapeutics (CERT). In addition to his research, Dr. Hennessy teaches clinical epidemiology to medical and graduate students, and is active in promoting evidence based practice at Penn, directing its Ambulatory Drug Use and Effects Program, and serving on its Pharmacy and Therapeutics Committee. Dr. Hennessy’s clinical program has received two Quality and Safety Awards from the University of Pennsylvania Health System. Dr. Hennessy received the 2005 Young Alumnus Award from the University of the Sciences in Philadelphia and the 2008 Leon I. Goldberg Young Investigator Award from the American Society for Clinical Pharmacology and Therapeutics.

  • David Margolis, MD, PhD

    Dr. Margolis's research work is focused on the epidemiology and treatment of chronic wounds. He currently is the Principal Investigator of several NIH, industry, and foundation grants, such as developing a prediction model for treating venous leg ulcers, creating prediction models for determining who will develop venous leg ulcers or pressure ulcers, and separate gene therapy phase I studies treating venous leg ulcers and diabetic foot ulcers. Dr. Margolis's clinical focus is on the treatment of chronic wounds of the skin. He was a board member of the National Pressure Advisory Panel, and of the Wound Healing Society. He is currently a board member of the International Dermato-epidemiology Association, Dermato-epidemiology Association Americas chapter and the Wound Healing Consortium. He is an Associate Editor of Pharmacoepidemiology and Drug Safety and is on the editorial boards of Archives of Dermatology, Journal of the American Academy of Dermatology, Wounds, Cocharane Wound Group, and Wound Repair and Regernation. He was a member of the Agency for Health Care Policy and Research Panel for the Treatment of Pressure Ulcers. In addition, he was a member of a NIH/NIAMS working group on dermato-epidemiology and NIH Interagency Coordinating Committee on Venous Stasis Ulcers, and was a member of the FDA-Biologics Chronic Wound Advisory Board. He serves on several Data Safety Monitoring boards. He has written more than 100 peer reviewed research or review publications and 10 book chapters.

  • Brian L. Strom, MD, MPH

    Dr. Strom earned a B.S. in Molecular Biophysics and Biochemistry from Yale University in 1971, and then an M.D. degree from the Johns Hopkins University School of Medicine in 1975. From 1975-1978 he was an intern and resident in Internal Medicine and from 1978-1980 he was an NIH fellow in Clinical Pharmacology at the University of California, San Francisco. He simultaneously earned an M.P.H. Degree in Epidemiology at the University of California, Berkeley. He has been on the faculty of the University of Pennsylvania School of Medicine since 1980. The Center for Clinical Epidemiology and Biostatistics that he has created at Penn includes over 550 faculty, research and support staff, and trainees. More than 500 clinicians have been trained or are in training through the CCEB's Master of Science in Clinical Epidemiology degree program. All but approximately 50 have appointments in academic or other research institutions. In this process, Dr Strom has become a leader in the rigorous formal training of clinical researchers. Although Dr. Strom's interests span many areas of clinical epidemiology, his major research interest is in the field of pharmacoepidemiology. In addition to writing more than 530 papers, he has been principal investigator for more than 245 grants, including over $73 million in direct costs alone. Dr. Strom has also made substantial contributions to many additional extramurally-funded grants. He has been invited to more than 385 talks outside his local area, including being the keynote speaker for numerous international meetings. Dr. Strom has been a consultant to NIH, FDA, CDC, USP, AAMC, JCAHO, foreign governments, most major pharmaceutical manufacturers, and many law firms. Dr. Strom was a member of the Board of Regents of the American College of Physicians, the Board of Directors of the American Society for Clinical Pharmacology and Therapeutics, and the Board of Directors for the American College of Epidemiology, and is currently a member of the Board of Directors for the Association for Patient-Oriented Research. He was previously President of the International Society for Pharmacoepidemiology and the Association for Clinical Research Training. He is currently a member of the American Epidemiology Society, and is one of a handful of clinical epidemiologists ever elected to the American Society of Clinical Investigation and American Association of Physicians.

  • Andrea B. Troxel, ScD

    Dr. Troxel's statistical research interests are in the areas of longitudinal studies, incomplete data, clinical trials, and statistical issues in the analysis of quality-of-life data. She has developed nonignorable missing data models for longitudinal data with complex missingness patterns. Recent work in missing data has focused on development of an index of sensitivity to nonignorability. She has also studied the particular methodological issues arising in the analysis of quality-of-life (QOL) data. More recently Dr. Troxel has focused on developing methods for joint analysis of repeated QOL and survival data. Dr. Troxel's medical research interests are primarily in oncology, where she has considerable experience in the design and analysis of both early-phase trials and randomized studies, as well as laboratory investigations and population-based research.